CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
90 hedge funds and large institutions have $148M invested in CTI BioPharma Corp. (DE) Common Stock in 2014 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 33 increasing their positions, 13 reducing their positions, and 16 closing their positions.
819% more call options, than puts
Call options by funds: $4.25M | Put options by funds: $462K
154% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 13
47% more capital invested
Capital invested by funds: $101M → $148M (+$47.6M)
38% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 16
6% more funds holding
Funds holding: 85 → 90 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$11.2M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.16M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$5.78M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$3.29M |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$978K |
| 2 |
Jane Street
New York
|
-$901K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$703K |
| 4 |
HCM
Highbridge Capital Management
New York
|
-$311K |
| 5 |
EEG
E.E. Geduld
|
-$97K |
CTIC Hedge Fund Activity: Q4 2014 in Review
90 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q4 2014, worth a combined $148M — up 47% from $101M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new CTIC positions and 16 closed out — a net gain of 6 holders — while 33 added to existing stakes and 13 trimmed.
The largest buyer was Eagle Asset Management, adding an estimated $11.2M. The largest seller was Renaissance Technologies, cutting an estimated $978K.
- 90 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q4 2014, up from 85 in Q3 2014.
- Funds reported $148M of CTI BioPharma Corp. (DE) Common Stock stock for Q4 2014, up 47% quarter-over-quarter.
- 22 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q4 2014 and 16 closed out, a net change of +6 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q4 2014 was Eagle Asset Management, an estimated $11.2M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q4 2014 was Renaissance Technologies, an estimated $978K sold.
Based on aggregated 13F filings for Q4 2014.